Literature DB >> 14766808

Acquisition of high-risk human papillomavirus infections and pap smear abnormalities among women in the New Independent States of the Former Soviet Union.

Stina Syrjänen1, Irena Shabalova, Nicolay Petrovichev, Vladimir Kozachenko, Tatjana Zakharova, Julia Pajanidi, Jurij Podistov, Galina Chemeris, Larisa Sozaeva, Elena Lipova, Irena Tsidaeva, Olga Ivanchenko, Alla Pshepurko, Sergej Zakharenko, Raisa Nerovjna, Ludmila Kljukina, Oksana Erokhina, Marina Branovskaja, Maritta Nikitina, Valerija Grunberga, Alexandr Grunberg, Anna Juschenko, Piero Tosi, Marcella Cintorino, Rosa Santopietro, Kari Syrjänen.   

Abstract

The rates of acquisition and the times of incident high-risk (HR) human papillomavirus (HPV) infections and Pap smear abnormalities and their predictive factors were analyzed in women participating in a multicenter screening study in three countries of the New Independent States of the former Soviet Union. The 423 patients were prospectively monitored for a mean of 21.6 months. At the baseline, 118 women were HR HPV DNA negative (Hybrid Capture II assay) and Pap smear negative (group 1), 184 were HPV DNA positive and Pap smear negative (group 2), and 121 were HPV DNA negative and Pap smear positive (group 3). The time to the acquisition of an incident abnormal Pap smear (19.4 months) was significantly longer in group 1 than in group 2 (9.2 months) (P = 0.0001). The times of acquisition of incident HR HPV infection were 16.6 and 11.0 months in group 1 and group 3, respectively (P = 0.006). The monthly rates of acquisition of incident HR HPV infections were very similar in group 1 (1.0%) and group 3 (0.8%), whereas the rate of acquisition of an abnormal Pap smear was significantly higher in group 2 (3.1%) than in group 1 (1.5%) (P = 0.0001). The acquisition of HR HPV infection (but not a positive Pap smear result) was significantly (P = 0.0001) age dependent. The only significant independent (P = 0.001) predictor of the incidence of an abnormal Pap smear result was a high HR HPV load of >20 relative light units/control value (CO) (rate ratio, 2.050; 95% confidence interval, 1.343 to 3.129). Independent predictors of incident HR HPV infection were patient category (a sexually transmitted disease) and ever having been pregnant. The time of acquisition of HR HPV infection was 3 months shorter than that of an abnormal Pap smear. At the baseline the high load of a particular HR HPV type is the single most important predictor of an incident Pap smear abnormality, whereas young age and having a sexually transmitted disease predict incident HR HPV infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14766808      PMCID: PMC344495          DOI: 10.1128/JCM.42.2.505-511.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer.

Authors:  H zur Hausen
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

Review 2.  Persistent human papillomavirus infection and cervical neoplasia.

Authors:  Alex Ferenczy; Eduardo Franco
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

3.  Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.

Authors:  A B Moscicki; N Hills; S Shiboski; K Powell; N Jay; E Hanson; S Miller; L Clayton; S Farhat; J Broering; T Darragh; J Palefsky
Journal:  JAMA       Date:  2001-06-20       Impact factor: 56.272

4.  Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions.

Authors:  K L Liaw; A G Glass; M M Manos; C E Greer; D R Scott; M Sherman; R D Burk; R J Kurman; S Wacholder; B B Rush; D M Cadell; P Lawler; D Tabor; M Schiffman
Journal:  J Natl Cancer Inst       Date:  1999-06-02       Impact factor: 13.506

5.  Incidence, clearance and predictors of human papillomavirus infection in women.

Authors:  John W Sellors; Tina L Karwalajtys; Janusz Kaczorowski; James B Mahony; Alice Lytwyn; Sylvia Chong; Joanna Sparrow; Attila Lorincz
Journal:  CMAJ       Date:  2003-02-18       Impact factor: 8.262

6.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer.

Authors:  E L Franco; L L Villa; J P Sobrinho; J M Prado; M C Rousseau; M Désy; T E Rohan
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

7.  The natural history of HPV infection of the uterine cervix. Long-term observational and histological data.

Authors:  Evangelos Paraskevaidis; Apostolos Kaponis; Vassiliki Malamou-Mitsi; Emma J Davidson; Pierre Martin Hirsch; George Koliopoulos; Lina Papp; Konstantinos Zikopoulos; Minas Paschopoulos; Evangelos Lolis; Panagiotis Stamatopoulos; Niki J Agnantis
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

8.  Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study.

Authors:  Susanne K Kjaer; Adriaan J C van den Brule; Gerson Paull; Edith I Svare; Mark E Sherman; Birthe L Thomsen; Mette Suntum; Johannes E Bock; Paul A Poll; Chris J L M Meijer
Journal:  BMJ       Date:  2002-09-14

9.  Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities.

Authors:  Mark Schiffman; Cosette M Wheeler; Philip E Castle
Journal:  J Infect Dis       Date:  2002-09-16       Impact factor: 5.226

10.  Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort.

Authors:  J M Deacon; C D Evans; R Yule; M Desai; W Binns; C Taylor; J Peto
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more
  7 in total

1.  Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women.

Authors:  Ann Nielsen; Thomas Iftner; Christian Munk; Susanne K Kjaer
Journal:  Sex Transm Dis       Date:  2009-10       Impact factor: 2.830

2.  Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic.

Authors:  Petroula Stamataki; Athanasia Papazafiropoulou; Ioannis Elefsiniotis; Margarita Giannakopoulou; Hero Brokalaki; Eleni Apostolopoulou; Pavlos Sarafis; George Saroglou
Journal:  BMC Infect Dis       Date:  2010-02-15       Impact factor: 3.090

3.  Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools.

Authors:  S-M Kulmala; S Syrjänen; I Shabalova; N Petrovichev; V Kozachenko; J Podistov; O Ivanchenko; S Zakharenko; R Nerovjna; L Kljukina; M Branovskaja; V Grunberga; A Juschenko; P Tosi; R Santopietro; K Syrjänen
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

4.  Population-based study of human papillomavirus infection and cervical neoplasia in Athens, Greece.

Authors:  C Kroupis; G Thomopoulou; T G Papathomas; N Vourlidis; A C Lazaris
Journal:  Epidemiol Infect       Date:  2007-06-07       Impact factor: 2.451

5.  Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study.

Authors:  Karolina Louvanto; Marjut A Rintala; Kari J Syrjänen; Seija E Grénman; Stina M Syrjänen
Journal:  BMC Infect Dis       Date:  2011-06-22       Impact factor: 3.090

6.  Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma.

Authors:  Pinaki Bose; Alexander C Klimowicz; Elizabeth Kornaga; Stephanie K Petrillo; T Wayne Matthews; Shamir Chandarana; Anthony M Magliocco; Nigel T Brockton; Joseph C Dort
Journal:  BMC Cancer       Date:  2012-08-01       Impact factor: 4.430

Review 7.  Worldwide incidence of cervical lesions: a systematic review.

Authors:  J Ting; A F Rositch; S M Taylor; L Rahangdale; H M Soeters; X Sun; J S Smith
Journal:  Epidemiol Infect       Date:  2014-05-30       Impact factor: 4.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.